Body Vision Medical Receives FDA Clearance for LungVision 2.0 System, a Part of LungVision Platform, Demonstrated at ATS 2019

Physicians explore how the cutting-edge technology helps them visualize, access and biopsy small lung lesions in real time with high accuracy, while in the standard bronchoscopy suite.   Body Vision Medical, a medical device company specializing in augmented real-time imaging, artificial intelligence and intra-body navigation, announced today that it has received clearance from the U.S.
Read more
No Comments

Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated

Fri, Dec 07, 2018 15:30 CET Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No dose limiting toxicities (DLTs) were reported at the highest dose level investigated, 10 mg/kg. According to the study protocol, the
Read more
No Comments

Roche launches the AVENIO Millisect System for precise and efficient dissection of tissue biopsies

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the commercial availability of the AVENIO Millisect System, a tissue dissection instrument that utilizes an automated digitally assisted process to reliably and efficiently isolate clinically relevant cells from formalin-fixed paraffin-embedded (FFPE) tissue slides.   The AVENIO Millisect System addresses challenges inherent in today’s tissue dissection practice in the
Read more
No Comments

Merck Develops Alternative CRISPR Genome Editing Method

– New technology to improve genome editing, advance new possibilities for research – Creates method to rapidly deploy newly discovered bacterial CRISPR systems in disease-specific applications – Research published in prestigious journal, Nature Communications Merck, a leading science and technology company, has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific,
Read more
No Comments

Mel-Mont Medical, LLC announces the development of Mía by XytoTest®, a self-collected cervical sample that seeks to eradicate cervical cancer

Mía by XytoTest® is a preventive comprehensive diagnostic system developed and patented by the American company, Mel-Mont Medical, LLC founded in 2014 by Frank Meléndez, MSc. and Liliana Montes, MSc. both medical device developers. This innovative system includes a medical device that allows women to self-collect cervical cells in any environment without assistance, to later
Read more
No Comments

Varian Launches Game-Changing Treatment Platform to Answer the Global Cancer Challenge.

Halcyon human-centered design revolutionizes clinical workflow; simplifies and enhances image-guided volumetric IMRT   Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT).  This new treatment system is
Read more
No Comments